Medical News

RSS

Mike Huckabee says GOP should focus more on health care in Presidential election

Former Republican presidential candidate and Arkansas Gov. Mike Huckabee on Tuesday during a forum about obesity expressed disappointment that the party has not focused more on health care in the presidential election, The Hill reports.

4 Sep 2008

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Anadis announced today its commercialization of a new product, BioGard, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

4 Sep 2008

Natural birth better for bonding baby and mother

American researchers are suggesting that natural birth may make mothers more responsive to their babies than those who choose to have a Caesarean.

4 Sep 2008

The power of cigarettes not just down to nicotine

According to new research from the U.S., it may not just be nicotine which gives cigarettes their power but rather how it enhances other experiences.

4 Sep 2008

Teenager almost deaf after waiting too long for ear drum surgery

In the latest bungle involving an Australian hospital, a teenage boy in Tasmania has reportedly waited so long for surgery to repair his perforated ear drum that he is almost deaf.

4 Sep 2008

Stress and depression compromising the safety of Australia's truck drivers

A new report raises concerns about the mental well being of many of Australia's truck drivers.

4 Sep 2008

CDC MMR/autism study - wrong questions asked, wrong children studied, wrong conclusions NAA says

A Centers for Disease Control and Prevention (CDC) study released today claims there is no link between the MMR vaccine and autism. The National Autism Association (NAA) says this study does nothing to dispel the growing public concern over a vaccine-autism connection and raises several questions concerning design and methodology.

4 Sep 2008

CDC MMR/autism study - wrong questions asked, wrong children studied, wrong conclusions NAA says

4 Sep 2008

Merck Serono and Ablynx to jointly develop nanobodies

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has entered into an agreement with Ablynx, to co-discover and co-develop Nanobodies against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of EUR10 million.

4 Sep 2008

Second phase 3 trial of Bronchitol in cystic fibrosis sufferers begins

Pharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

4 Sep 2008

Hallucinations in the flash of an eye

Ever seen or heard something that wasn't there? For most of us such experiences - termed hallucinations - are a normal, fleeting, brain glitch; yet for a few they are persistent, distressing and associated with a range of psychiatric, neurological and eye conditions.

4 Sep 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Diffusion Pharmaceuticals initiates phase I/II clinical trial in patients with peripheral arterial disease

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC).

3 Sep 2008

Vimpat (lacosamide) approved in Europe

UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.

3 Sep 2008

Biovail files abbreviated new drug application for Fenofibrate tablets

Biovail Corporation today announced that the United States Food and Drug Administration (FDA) has accepted the Company's abbreviated new drug application (ANDA) for a generic formulation of 145mg and 48mg strengths of fenofibrate tablets (sold under the brand name Tricor by Abbott Laboratories).

3 Sep 2008

Alte Biosciences files patent for novel inflammatory bowel disease drugs

Alte Bioscience, Inc., a development stage pharmaceutical company, is pleased to announce the filing of a provisional patent for a new class of drugs that may benefit patients with inflammatory bowel disease.

3 Sep 2008

A home early warning system for cardiac patients

Heart disease is the number one cause of death in Europe and early diagnosis is essential to save lives. Monitoring the heart's rhythm and electrical activity in real time using an electrocardiogram (ECG) provides vital information about abnormalities and gives clues to the nature of a problem. Some cardiac conditions need long-term monitoring - inconvenient for patients as it requires them to be away from their everyday environment for indeterminate periods of time.

3 Sep 2008

Exercise reduces damage after therapeutic irradiation to the brain

Researchers at the Sahlgrenska Academy in Gothenburg show for the first time that exercise helps restore stem cell growth and improves behavior in young mice that suffered damage to the brain induced by a clinically relevant dose of radiation. The researchers believe that these results are also applicable to children that have suffered damage due to radiotherapy of brain tumors.

3 Sep 2008

National Toxicology Program finalizes report on Bisphenol A

Current human exposure to bisphenol A (BPA), a chemical used in many polycarbonate plastics and epoxy resins, is of "some concern" for effects on development of the prostate gland and brain and for behavioral effects in fetuses, infants and children, according to a final report released today by the National Toxicology Program (NTP).

3 Sep 2008